Consun Pharmaceutical Group (FRA:C1P) Debt-to-Equity : 0.14 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Consun Pharmaceutical Group Debt-to-Equity?

Consun Pharmaceutical Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €65.2 Mil. Consun Pharmaceutical Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.5 Mil. Consun Pharmaceutical Group's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €465.7 Mil. Consun Pharmaceutical Group's debt to equity for the quarter that ended in Dec. 2023 was 0.14.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Consun Pharmaceutical Group's Debt-to-Equity or its related term are showing as below:

FRA:C1P' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.14 Med: 0.23 Max: 0.33
Current: 0.14

During the past 12 years, the highest Debt-to-Equity Ratio of Consun Pharmaceutical Group was 0.33. The lowest was 0.14. And the median was 0.23.

FRA:C1P's Debt-to-Equity is ranked better than
66.39% of 842 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs FRA:C1P: 0.14

Consun Pharmaceutical Group Debt-to-Equity Historical Data

The historical data trend for Consun Pharmaceutical Group's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Consun Pharmaceutical Group Debt-to-Equity Chart

Consun Pharmaceutical Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.28

0.25

0.23

0.15

0.14

Consun Pharmaceutical Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.23	0.17	0.15	0.16	0.14

Competitive Comparison of Consun Pharmaceutical Group's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Consun Pharmaceutical Group's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Consun Pharmaceutical Group's Debt-to-Equity falls into.

Consun Pharmaceutical Group Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Consun Pharmaceutical Group's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(65.195	+	0.501)	/	465.744
	=	0.14

Consun Pharmaceutical Group's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(65.195	+	0.501)	/	465.744
	=	0.14

Consun Pharmaceutical Group (FRA:C1P) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Consun Pharmaceutical Group Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Consun Pharmaceutical Group's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Consun Pharmaceutical Group (FRA:C1P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Consun Pharmaceutical Group Ltd (FRA:C1P) » Definitions » Debt-to-Equity

Traded in Other Exchanges

01681:Hong Kong

Address

71, Dongpeng Avenue, Eastern section, Guangzhou Economic and Technological Development, Guangzhou, CHN

Website

https://www.chinaconsun.com

Consun Pharmaceutical Group Ltd is a biotechnology company with sales operations throughout China. Its principal activities are making and selling pharmaceutical products. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Consun derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.

Consun Pharmaceutical Group (FRA:C1P) Headlines

No Headlines